Related Experiment Video
Updated: May 14, 2026
11:33
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
Published on: March 12, 2013
Primary aldosteronism and potassium channel mutations.
1Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Greenslopes and Princess Alexandra Hospitals, Brisbane, Australia. m.stowasser@uq.edu.au
Current Opinion in Endocrinology, Diabetes, and Obesity
|February 22, 2013
Summary
Mutations in potassium channel genes, particularly KCNJ5, are key to primary aldosteronism. These genetic changes affect ion flow, increasing aldosterone production and potentially leading to new diagnostic and treatment strategies.
Area of Science:
- Endocrinology
- Genetics
- Molecular Biology
Background:
- Primary aldosteronism is a condition characterized by excessive aldosterone production.
- Potassium channel gene mutations are increasingly recognized as a factor in its development.
Purpose of the Study:
- To review recent research on potassium channel gene mutations in primary aldosteronism.
- To discuss the implications of these findings for understanding the disease's pathogenesis.
Main Methods:
- Review of current scientific literature on potassium channel genes and primary aldosteronism.
- Analysis of genotype-phenotype correlations in familial and sporadic cases.
Main Results:
- Potassium channel gene variants (Kcnma1, TASK-1, TASK-3, HERG, KCNJ5) are linked to primary aldosteronism in animals and humans.
- KCNJ5 mutations, both germline and somatic, are significant contributors, affecting ion selectivity and leading to increased aldosterone synthesis.
- Somatic KCNJ5 mutations are found in about 40% of aldosterone-producing adenomas, associated with specific clinical and histological features.
Conclusions:
- Potassium channel gene mutations provide critical insights into primary aldosteronism pathophysiology.
- These discoveries may pave the way for novel diagnostic tools and therapeutic interventions.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:26Voltage-gated Ion Channels
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
01:26Voltage-gated Ion Channels
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:24Non-gated Ion Channels
Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.